β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Adrenergic beta-Agonists/*pharmacology ; Adrenergic beta-Antagonists/*pharmacology ; Cyclic AMP/*metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 3/*metabolism ; Muscle, Smooth, Vascular/*drug effects ; Myocytes, Smooth Muscle/*drug effects; Animals ; Aorta/cytology ; Aorta/drug effects ; Aorta/metabolism ; Cell Membrane/drug effects ; Cell Membrane/enzymology ; Cyclic Nucleotide Phosphodiesterases, Type 1/antagonists & inhibitors ; Cyclic Nucleotide Phosphodiesterases, Type 1/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 7/metabolism ; Fluorescence Resonance Energy Transfer ; Isoproterenol/pharmacology ; Muscle, Smooth, Vascular/cytology ; Muscle, Smooth, Vascular/enzymology ; Myocytes, Smooth Muscle/cytology ; Myocytes, Smooth Muscle/enzymology ; Phosphodiesterase Inhibitors/pharmacology ; Primary Cell Culture ; Rats ; Signal Transduction/drug effects ; Signal Transduction/physiology ; Time Factors
    • Abstract:
      Background: We investigated the role of cyclic nucleotide phosphodiesterases (PDEs) in the spatiotemporal control of intracellular cAMP concentrations in rat aortic smooth muscle cells (RASMCs).
      Methodology/principal Findings: The rank order of PDE families contributing to global cAMP-PDE activity was PDE4> PDE3  =  PDE1. PDE7 mRNA expression but not activity was confirmed. The Fluorescence Resonance Energy Transfer (FRET)-based cAMP sensor, Epac1-camps, was used to monitor the time course of cytosolic cAMP changes. A pulse application of the β-adrenoceptor (β-AR) agonist isoproterenol (Iso) induced a transient FRET signal. Both β(1)- and β(2)-AR antagonists decreased the signal amplitude without affecting its kinetics. The non-selective PDE inhibitor (IBMX) dramatically increased the amplitude and delayed the recovery phase of Iso response, in agreement with a role of PDEs in degrading cAMP produced by Iso. Whereas PDE1, PDE3 and PDE7 blockades [with MIMX, cilostamide (Cil) and BRL 50481 (BRL), respectively] had no or minor effect on Iso response, PDE4 inhibition [with Ro-20-1724 (Ro)] strongly increased its amplitude and delayed its recovery. When Ro was applied concomitantly with MIMX or Cil (but not with BRL), the Iso response was drastically further prolonged. PDE4 inhibition similarly prolonged both β(1)- and β(2)-AR-mediated responses. When a membrane-targeted FRET sensor was used, PDE3 and PDE4 acted in a synergistic manner to hydrolyze the submembrane cAMP produced either at baseline or after β-AR stimulation.
      Conclusion/significance: Our study underlines the importance of cAMP-PDEs in the dynamic control of intracellular cAMP signals in RASMCs, and demonstrates the prominent role of PDE4 in limiting β-AR responses. PDE4 inhibition unmasks an effect of PDE1 and PDE3 on cytosolic cAMP hydrolyzis, and acts synergistically with PDE3 inhibition at the submembrane compartment. This suggests that mixed PDE4/PDE1 or PDE4/PDE3 inhibitors would be attractive to potentiate cAMP-related functions in vascular cells.
    • References:
      Circ Res. 2008 May 9;102(9):1091-100. (PMID: 18369156)
      Br J Pharmacol. 1999 Sep;128(1):69-76. (PMID: 10498836)
      J Mol Cell Cardiol. 2012 Feb;52(2):323-9. (PMID: 21888909)
      Physiol Rev. 2004 Jul;84(3):767-801. (PMID: 15269336)
      J Biol Chem. 1971 May 25;246(10):3145-50. (PMID: 4324892)
      J Gen Physiol. 2001 Jul;118(1):63-78. (PMID: 11429444)
      Can J Physiol Pharmacol. 1994 Nov;72(11):1380-5. (PMID: 7767882)
      Cardiovasc Res. 2008 Jan;77(1):202-10. (PMID: 18006484)
      Br J Pharmacol. 1996 Oct;119(3):471-8. (PMID: 8894166)
      Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):365-70. (PMID: 18165313)
      Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):452-63. (PMID: 15599707)
      Arterioscler Thromb Vasc Biol. 2000 May;20(5):1225-35. (PMID: 10807737)
      Mol Pharmacol. 2004 Dec;66(6):1679-89. (PMID: 15371556)
      Mol Pharmacol. 2002 May;61(5):1033-40. (PMID: 11961121)
      J Biol Chem. 1997 Mar 14;272(11):6823-6. (PMID: 9102399)
      Eur J Pharmacol. 2009 Oct 12;620(1-3):78-83. (PMID: 19686719)
      J Cell Physiol. 2001 Jan;186(1):1-10. (PMID: 11147803)
      Mol Pharmacol. 2000 Aug;58(2):247-52. (PMID: 10908291)
      Physiology (Bethesda). 2006 Apr;21:86-92. (PMID: 16565474)
      Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. (PMID: 14730417)
      Mol Pharmacol. 2003 Sep;64(3):533-46. (PMID: 12920188)
      Circulation. 2006 May 9;113(18):2221-8. (PMID: 16651469)
      Methods Enzymol. 1988;159:489-96. (PMID: 2457788)
      J Gen Physiol. 2006 Jul;128(1):3-14. (PMID: 16769793)
      Neuropharmacology. 2004 Dec;47(7):1081-92. (PMID: 15555642)
      J Biol Chem. 1986 Nov 5;261(31):14740-5. (PMID: 3533925)
      Biochem Pharmacol. 2000 Feb 15;59(4):347-56. (PMID: 10644042)
      Ann N Y Acad Sci. 2006 Oct;1080:348-61. (PMID: 17132794)
      J Clin Invest. 1997 Nov 15;100(10):2611-21. (PMID: 9366577)
      J Biol Chem. 2004 Sep 3;279(36):37215-8. (PMID: 15231839)
      Br J Pharmacol. 1997 Sep;122(2):233-40. (PMID: 9313930)
      Am J Physiol Cell Physiol. 2010 Feb;298(2):C324-32. (PMID: 19889965)
      J Biol Chem. 2000 Aug 25;275(34):26615-24. (PMID: 10851231)
      J Cell Sci. 2010 Jan 1;123(Pt 1):95-106. (PMID: 20016070)
      EMBO J. 2008 Jan 23;27(2):384-93. (PMID: 18188154)
      J Clin Invest. 2008 Aug;118(8):2747-57. (PMID: 18636120)
      Pharmacol Rev. 2001 Jun;53(2):319-56. (PMID: 11356987)
      Am J Physiol Lung Cell Mol Physiol. 2005 Jan;288(1):L103-15. (PMID: 15377497)
      Circ Res. 2006 Oct 13;99(8):816-28. (PMID: 17038651)
      Mol Pharmacol. 2002 Nov;62(5):983-92. (PMID: 12391260)
      Br J Pharmacol. 2000 Feb;129(4):637-44. (PMID: 10683187)
      Circ Res. 2006 Nov 10;99(10):1084-91. (PMID: 17038640)
      Arteriosclerosis. 1990 Nov-Dec;10(6):966-90. (PMID: 2244864)
      Circ Res. 2007 Feb 16;100(3):309-27. (PMID: 17307970)
      Br J Pharmacol. 2002 Sep;137(2):153-61. (PMID: 12208771)
      Circ Res. 2011 Jul 8;109(2):231-44. (PMID: 21737818)
    • Accession Number:
      0 (Adrenergic beta-Agonists)
      0 (Adrenergic beta-Antagonists)
      0 (Phosphodiesterase Inhibitors)
      E0399OZS9N (Cyclic AMP)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 1)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 7)
      L628TT009W (Isoproterenol)
    • Publication Date:
      Date Created: 20121025 Date Completed: 20130401 Latest Revision: 20241103
    • Publication Date:
      20241103
    • Accession Number:
      PMC3475707
    • Accession Number:
      10.1371/journal.pone.0047826
    • Accession Number:
      23094097